Recombinant Cynomolgus/Rhesus CD83 protein, hFc-tagged

• Cat.No.: CD83-102C
• Product Overview: Recombinant Cynomolgus/Rhesus CD83 protein(F6WX37)(Met1-Ala143), fused with hFc tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Cynomolgus/Rhesus
• Tag: Fc
• Form: Lyophilized from sterile PBS, pH 7.4Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
• Molecular Mass: The recombinant cynomolgus / rhesus CD83 is a disulfide-linked homodimer. The reduced monomer comprises 365 amino acids and has a calculated molecular mass of 41 KDa.The apparent molecular mass of the protein is approximately 45-55 and 34 KDa respectively in SDS-PAGE.
• Protein length: Met1-Ala143
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 95 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C
  Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Reviews

03/16/2021

The experimental conditions are wide, and the experimental results are accurate and reproducible.

08/24/2020

The resulting strips are clear and bright, which greatly exceeds the expected results.

06/10/2020

CD83 activity is maintained for a very long time and can be maintained for a long time, which is very stable and reliable.

Q&As

Could CD83 be a target for immunotherapy?

Yes, CD83 can be targeted as immunotherapy. Immunotherapy for CD83 has been explored in several clinical trials with some efficacy.

Are there population differences in CD83 treatment?

It is unclear whether there is a population difference in CD83 treatment. However, due to factors such as individual differences and genetic polymorphisms, different populations may respond differently to treatment. Therefore, population-specific treatment strategies may need to be individually adapted and optimized.

What are possible aspects of future research on CD83?

Future research on CD83 may involve more in-depth molecular mechanism studies, optimization and improvement of CD83-based immunotherapy strategies, and research on combination with other immunotherapies or drugs.

Is there a relationship between CD83 and other immune checkpoint molecules?

CD83 interacts and regulates with other immune checkpoint molecules. Together, they are involved in the regulation of the immune response.

Is CD83 expression regulated by other molecules?

Yes, CD83 expression is regulated by a variety of molecules, including cytokines, transcription factors, and epigenetic modifications.

What is the therapeutic approach for CD83?

Current treatments for CD83 mainly include immunotherapy and gene therapy. Immunotherapy against CD83 works primarily by modulating the function of dendritic cells and T cells.